Antibodies to Microtubule-Associated Protein 2 in Patients With Neuropsychiatric Systemic Lupus Erythematosus

Ralph C. Williams, Kazumitsu Sugiura, Eng M. Tan

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Objective. Microtubule-associated protein 2 (MAP-2), a cellular protein restricted to neurons, is important in the control of cytoskeletal integrity and other neuronal functions. We undertook this study to examine the presence of autoantibodies to MAP-2 in neuropsychiatric systemic lupus erythematosus (NPSLE). Methods. Sera from 100 patients with SLE, 74 patients witli other neurologic disorders and injuries (including cerebrovascular accidents, brain trauma, brain tumors, and demyelinating disorders), and 60 normal controls were examined both by enzyme immunoassays and by Western immunoblotting for autoantibodies to MAP-2. Sera designated positive for antibodies to MAP-2 were required to be positive in both assays. Results. Seventeen percent of SLE patients had autoantibodies to MAP-2, in contrast to 4% of neurologic injury/disease control patients (P = 0.028) and 1.7% of normal controls. In SLE, anti-MAP-2 positivity in both assays was associated with neuropsychiatric symptoms in 76.5% of patients, whereas the absence of anti-MAP-2 was associated with neuropsychiatric symptoms in 19.7% of patients (P = 0.0002). The neuropsychiatric symptoms in the former group included psychosis, seizure, neuropathy, and cerebritis. Conclusion. Autoantibodies to MAP-2, a neuron-restricted cytoskeletal protein, appear to be another immune marker for NPSLE.

Original languageEnglish
Pages (from-to)1239-1247
Number of pages9
JournalArthritis and Rheumatism
Volume50
Issue number4
DOIs
Publication statusPublished - 01-04-2004

Fingerprint

Central Nervous System Lupus Vasculitis
Microtubule-Associated Proteins
Antibodies
Autoantibodies
Nervous System Trauma
Nervous System Diseases
Neurons
Cytoskeletal Proteins
Brain Diseases
Demyelinating Diseases
Serum
Immunoenzyme Techniques
Brain Neoplasms
Psychotic Disorders
Seizures
Biomarkers
Western Blotting
Stroke

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Cite this

@article{8b8cae91cccb44869fb7d9713292945b,
title = "Antibodies to Microtubule-Associated Protein 2 in Patients With Neuropsychiatric Systemic Lupus Erythematosus",
abstract = "Objective. Microtubule-associated protein 2 (MAP-2), a cellular protein restricted to neurons, is important in the control of cytoskeletal integrity and other neuronal functions. We undertook this study to examine the presence of autoantibodies to MAP-2 in neuropsychiatric systemic lupus erythematosus (NPSLE). Methods. Sera from 100 patients with SLE, 74 patients witli other neurologic disorders and injuries (including cerebrovascular accidents, brain trauma, brain tumors, and demyelinating disorders), and 60 normal controls were examined both by enzyme immunoassays and by Western immunoblotting for autoantibodies to MAP-2. Sera designated positive for antibodies to MAP-2 were required to be positive in both assays. Results. Seventeen percent of SLE patients had autoantibodies to MAP-2, in contrast to 4{\%} of neurologic injury/disease control patients (P = 0.028) and 1.7{\%} of normal controls. In SLE, anti-MAP-2 positivity in both assays was associated with neuropsychiatric symptoms in 76.5{\%} of patients, whereas the absence of anti-MAP-2 was associated with neuropsychiatric symptoms in 19.7{\%} of patients (P = 0.0002). The neuropsychiatric symptoms in the former group included psychosis, seizure, neuropathy, and cerebritis. Conclusion. Autoantibodies to MAP-2, a neuron-restricted cytoskeletal protein, appear to be another immune marker for NPSLE.",
author = "Williams, {Ralph C.} and Kazumitsu Sugiura and Tan, {Eng M.}",
year = "2004",
month = "4",
day = "1",
doi = "10.1002/art.20156",
language = "English",
volume = "50",
pages = "1239--1247",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

Antibodies to Microtubule-Associated Protein 2 in Patients With Neuropsychiatric Systemic Lupus Erythematosus. / Williams, Ralph C.; Sugiura, Kazumitsu; Tan, Eng M.

In: Arthritis and Rheumatism, Vol. 50, No. 4, 01.04.2004, p. 1239-1247.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antibodies to Microtubule-Associated Protein 2 in Patients With Neuropsychiatric Systemic Lupus Erythematosus

AU - Williams, Ralph C.

AU - Sugiura, Kazumitsu

AU - Tan, Eng M.

PY - 2004/4/1

Y1 - 2004/4/1

N2 - Objective. Microtubule-associated protein 2 (MAP-2), a cellular protein restricted to neurons, is important in the control of cytoskeletal integrity and other neuronal functions. We undertook this study to examine the presence of autoantibodies to MAP-2 in neuropsychiatric systemic lupus erythematosus (NPSLE). Methods. Sera from 100 patients with SLE, 74 patients witli other neurologic disorders and injuries (including cerebrovascular accidents, brain trauma, brain tumors, and demyelinating disorders), and 60 normal controls were examined both by enzyme immunoassays and by Western immunoblotting for autoantibodies to MAP-2. Sera designated positive for antibodies to MAP-2 were required to be positive in both assays. Results. Seventeen percent of SLE patients had autoantibodies to MAP-2, in contrast to 4% of neurologic injury/disease control patients (P = 0.028) and 1.7% of normal controls. In SLE, anti-MAP-2 positivity in both assays was associated with neuropsychiatric symptoms in 76.5% of patients, whereas the absence of anti-MAP-2 was associated with neuropsychiatric symptoms in 19.7% of patients (P = 0.0002). The neuropsychiatric symptoms in the former group included psychosis, seizure, neuropathy, and cerebritis. Conclusion. Autoantibodies to MAP-2, a neuron-restricted cytoskeletal protein, appear to be another immune marker for NPSLE.

AB - Objective. Microtubule-associated protein 2 (MAP-2), a cellular protein restricted to neurons, is important in the control of cytoskeletal integrity and other neuronal functions. We undertook this study to examine the presence of autoantibodies to MAP-2 in neuropsychiatric systemic lupus erythematosus (NPSLE). Methods. Sera from 100 patients with SLE, 74 patients witli other neurologic disorders and injuries (including cerebrovascular accidents, brain trauma, brain tumors, and demyelinating disorders), and 60 normal controls were examined both by enzyme immunoassays and by Western immunoblotting for autoantibodies to MAP-2. Sera designated positive for antibodies to MAP-2 were required to be positive in both assays. Results. Seventeen percent of SLE patients had autoantibodies to MAP-2, in contrast to 4% of neurologic injury/disease control patients (P = 0.028) and 1.7% of normal controls. In SLE, anti-MAP-2 positivity in both assays was associated with neuropsychiatric symptoms in 76.5% of patients, whereas the absence of anti-MAP-2 was associated with neuropsychiatric symptoms in 19.7% of patients (P = 0.0002). The neuropsychiatric symptoms in the former group included psychosis, seizure, neuropathy, and cerebritis. Conclusion. Autoantibodies to MAP-2, a neuron-restricted cytoskeletal protein, appear to be another immune marker for NPSLE.

UR - http://www.scopus.com/inward/record.url?scp=1842783796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842783796&partnerID=8YFLogxK

U2 - 10.1002/art.20156

DO - 10.1002/art.20156

M3 - Article

C2 - 15077307

AN - SCOPUS:1842783796

VL - 50

SP - 1239

EP - 1247

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 4

ER -